Russian pharmaceutical company GeroPharm is working on an oral medication for obesity, company head Pyotr Rodyonov revealed. Currently, most obesity treatments are administered via injections.
“The efficacy and tolerability of a medication can vary depending on individual patient characteristics. Therefore, having options between different forms is critically important. We are developing a tablet-based treatment for obesity to address this need,” Rodyonov told TASS during the Bioprom forum in Gelendzhik.
The general director also mentioned that the company is working on five additional drugs related to obesity and diabetes. He noted that, according to the Ministry of Health, if current trends persist, approximately half of Russians will be obese by 2030. Rodyonov emphasized that obesity levels are already high and, without intervention, could double within five years.
Additionally, Rodyonov announced that GeroPharm has registered Semavik, its generic version of Danish Novo Nordisk’s diabetes drug Ozempic, in Paraguay. The company plans to register the generic drug in two more countries by the end of the year, though Rodyonov did not specify which ones.
Obesity treatments have become a major focus in recent years, with pharmaceutical companies vying for market leadership — a trend explored by GxP News.